Seite auswählen

In June, the Deutschen Gesellschaft für Wundheilung und Wundbehandlung e. V. (DGfW) published the S3 guideline „Lokaltherapie chronischer Wunden bei den Risiken CVI, PAVK und Diabetes mellitus“. The editors argue that, for the approval of wound dressings, no clinical proof is required in controlled studies. Therefore, there are very few studies which are based on high quality evidence, since the superiority of individual wound products are not yet be properly substantiated.

Therefore, the S3 guideline concludes that the physician should make their decision in the selection of materials according to patient comfort, wound management, cost and individual experiences.

Commentary: Clinical studies in which different products are compared with each other for healing wounds are expensive and not required for the sale of products. They also involve the risk that the result might not turn out so clearly in favour of a product, as the initiator may have predicted. Therefore, it will continue to be a juxtaposition of products with different conclusions about their effectiveness and the doctor has to rely on his knowledge gained from previous applications. For manufacturers, the question remains, what trends are in the market for advanced wound care products, in order to identify which will win over the other.

[ilink url=“http://www.aerztezeitung.de/medizin/krankheiten/haut-krankheiten/article/819851/chronische-wunden-wundversorgung-zwischen-evidenz-erfahrung.html“]Link zur Quelle (Ärztezeitung)[/ilink]